Last reviewed · How we verify
NCT03519776
Variation of Progesterone in IVF Cycles
trial testing Progesterone variation in Progesterone Resistance in 30 participants. Completed in 31 March 2019.
28 February 2019
Quick facts
| Lead sponsor | ART Fertility Clinics LLC |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 10 May 2018 |
| Primary completion | 28 February 2019 |
| Estimated completion | 31 March 2019 |
| Sites | 1 location across United Arab Emirates |
Drugs / interventions tested
- Progesterone variation
Conditions studied
- Progesterone Resistance — all drugs for Progesterone Resistance →
Sponsor
ART Fertility Clinics LLC
Who can join
Adults 18 to 45, female only, with Progesterone Resistance. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
to examine if a natural daytime variation in progesterone levels may explain parts of the inconsistent findings from studies reporting divergent results concerning this matter and will be carried out by several blood samples from the same patient during the day of ovulation triggering.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Significant Serum Progesterone Variations on the Day of Final Oocyte Maturation in Stimulated IVF Cycles.
Shanker U, Lawrenz B, Bungum L, Depret Bixio L, et al · · 2019 · cited 3× · PMID 31824423 · DOI 10.3389/fendo.2019.00806
Verify or expand the search:
- PubMed search for NCT03519776
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Progesterone Resistance
Currently open trials in the same condition.
- NCT06390904 — GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients · Phase 2, PHASE3 · active not recruiting
- NCT06379113 — GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients · Phase 2, PHASE3 · recruiting
- NCT05316935 — GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients · Phase 2, PHASE3 · recruiting
Other ART Fertility Clinics LLC trials
Trials by the same sponsor.
- NCT07270250 — Impact of Dry vs Humidified Culture Conditions on Blastocyst Development and Aneuploidy: A Time-lapse Sibling Oocyte Stu · NA · not yet recruiting
- NCT06879002 — Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to · not yet recruiting
- NCT07093619 — Evaluating the Utility of Implementing Microfluids for Sperm Preparation Compared to Conventional Method of Density Grad · NA · recruiting
- NCT06732843 — Does Recombinant FSH (rFSH, i.g. Gonal F®) as Compared to Human Menopausal Gonadotrophin (hMG) Affect Telomere Length of · recruiting
- NCT07014267 — Virtual Reality for Mindfulness and Anxiety Reduction in Fertility Procedures · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03519776 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ART Fertility Clinics LLC
- Last refreshed: 26 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03519776.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing